Core Scientific, Inc. Tranche 2 Warrants financials
$16.67−5.50%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $319.0M | $510.7M |
| Gross profit | $37.9M | $121.1M |
| Gross margin | 11.9% | 23.7% |
| Operating income | -$256.3M | -$11.2M |
| Net income | -$280.7M | -$1.25B |
| Net margin | −88.0% | −243.9% |
| Diluted EPS | $-0.88 | $-4.87 |
| EBITDA | -$155.6M | $102.0M |
| Operating cash flow | $278.3M | $42.9M |
| Free cash flow | -$450.8M | -$52.1M |
| Diluted shares | 318.1M | 255.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $311.4M | $836.2M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $1.06B | $1.09B |
| Total assets | $2.35B | $1.48B |
| Total liabilities | $3.31B | $2.41B |
| Shareholders' equity | -$962.7M | -$938.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology